Skip to content

Usage of cookies

We would like to use cookies to better understand your use of this website. This enables us to improve your future experience on our website. Detailed information about the use of cookies on this website and how you can manage or withdraw your consent at any time can be found in our privacy policy.

Changing the way
we see the gut

Motilent specialises in the assessment of digestive diseases using medical image analysis. Our main focus areas include Crohn’s Disease, Irritable Bowel Syndrome (IBS) and Gastroparesis although we support a range of projects across the digestive health.

Understanding gastrointestinal disease

Motilent is a technology company focused on delivering innovative services for the quantitative investigation of the gut.

About

Motilent’s mission is to change the way we see the gut. We have spent the last 5 years developing new imaging technology that is helping researchers and clinicians understand how the digestive tract works.

Research

Motilent works closely with the research community, providing a range of products, services and expertise to further our understanding of gastrointestinal function.

GIQuant®

GIQuant®, is the first CE marked medical device for the quantification of dynamic MRI scans capturing small bowel movement.

Dynamic ‘cine’ MRI offers a new and potentially powerful perspective on gastrointestinal function, especially in conditions like Crohn’s where hypo-motility is related to disease activity. Objective assessment of this data with GIQuant could represent an important advance in how we quantify this in the clinic

Stuart A Taylor, Consultant Radiologist and Professor of Medical Imaging, UCL

Who we work with

Latest News

Alex Menys on The Health-tech Podcast

19th July 2020

Motilent’s CEO and Founder, Alex Menys speaks with Dr James Somauroo on The Health-Tech podcast. In the show Alex and James talk about the challenges of getting a product to market in the Med-Tech space as well as the the role of regulations, evidence and relationship building with the clinical community. There’s also a good […]

Motilent & Partners Receive Prestigious UKRI Funding

3rd July 2020

Crohn’s Disease is a chronic inflammatory condition of the intestine affecting people of all ages. There is an urgent need for technology to guide the use of powerful and expensive anti-inflammatory medications. Motilent has been awarded  a prestigious UKRI grant to tackle this challenge. About the project Motilent has been awarded a UKRI grant to […]

Anatomy Lesson

2nd July 2020

MRI or Magnetic Resonance Imaging is a safe, non-invasive and powerful test to look at a persons insides. It’s especially good for looking at soft tissue like muscle and organs like the brain, liver and digestive system. Motilent generates a lot of content around MRI and the intestine and this is a quick recap for […]

Past, Present and Future – a long journey living with Crohn’s Disease: Part 1

1st June 2020

A patients perspective on living with Crohn’s Disease, by Nigel Horwood Crohn’s is a chronic, inflammatory disease affecting the digestive tract and the incidence is on the increase Treatment options have come a long way but as yet there is no cure so attaining remission is the primary goal As we make real progress treating […]

Motilent appoints Laurence Bourn as Chief Technical Officer

9th October 2019

We are delighted to announce that Laurence Bourn has joined the Motilent team as Chief Technical Officer. Laurence started working with Motilent in August 2019 and will lead the growth of the Company’s technical operations as it enters the clinic. Laurence has 20 years of commercial experience within the medical device industry. He began as […]

G.I. Know – The Health Data Research Hub for Inflammatory Bowel Disease

17th September 2019

Great news for patients and researchers working in Inflammatory Bowel disease. Read more here: https://www.hdruk.ac.uk/infrastructure/the-hubs/g-i-know/

Location

IDEALondon, 69 Wilson Street, London EC2A 2BB


Email us